Certara Completes Acquisition of Chemaxon

Written by Customer Service on . Posted in Mergers And Acquisitions.

The combined organization offers life sciences companies predictive biosimulation and scientific informatics capabilities, improving certainty in decision-making from discovery through commercialization.

RADNOR, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) — Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced it has completed the acquisition of Chemaxon.

Chemaxon develops leading scientific informatics software products used by the life sciences industry for in-silico research. Certara develops advanced modeling and biosimulation solutions used to predict the pharmacokinetic and pharmacodynamic properties of large and small molecules.

“Combining Chemaxon’s expertise with Certara’s biosimulation capabilities provides life sciences companies with unique solutions to enhance productivity and increase their scientific innovation success rates,” said William Feehery, Certara’s CEO. “Together, we offer scientists more precise insights throughout drug discovery and development.” 

Near-term priorities for the combined organization include incorporating precision chemistry structures, calculators, and predictors into the Certara D360 scientific informatics applications and Simcyp™ PBPK Simulator for improved prediction accuracy. Longer-term plans include leveraging Certara.AI’s life sciences specialized GPT capabilities and bringing knowledge of pharmacokinetics and pharmacodynamics more broadly into the drug discovery process and Chemaxon products including Design Hub and JChem Engines.

“Our teams are excited to have an even greater impact on drug discovery and development practices,” said Richard Jones, Chemaxon CEO. “As pipelines shift to precision medicine therapies, accurate scientific predictions and biosimulation are more crucial to success than ever.” 

In 2024, Chemaxon is expected to generate software revenue greater than $20 million. Certara will update its 2024 guidance to include the contribution from Chemaxon when the Company reports third-quarter earnings in November.

A “frequently asked questions” document regarding the transaction is available on the Company’s investor relations website.

About Certara 

Certara accelerates medicines using biosimulation software, technology, and services to transform traditional drug discovery and development. Its clients include more than 2,400 biopharmaceutical companies, academic institutions, and regulatory agencies across 66 countries. Learn more at certara.com. 

About Chemaxon 

Chemaxon is a leading cheminformatics company that provides platforms, applications, and solutions to handle chemical entities in life sciences, biotechnology, agrochemicals, new materials, education, and other research industries. Its products and services help the capture and processing of chemical information that increases its value and results in more efficient decision-making for life sciences and other R&D environments. Learn more at chemaxon.com.  

Certara Contact: 
Sheila Rocchio 
sheila.rocchio@certara.com  

Media Contact: 
Alyssa Horowitz 
certara@pancomm.com 

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.